Regenxbio IncNASDAQ:RGNX
- LAST PRICE12.4100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.9700/ 2
- Ask / Lots19.8500/ 2
- Open / Previous Close0.0000 / 12.4100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 5831 | 12.91 |
| 09:34 ET | 1271 | 12.82 |
| 09:38 ET | 300 | 12.89 |
| 09:43 ET | 1265 | 12.85 |
| 09:45 ET | 500 | 12.9 |
| 09:48 ET | 300 | 12.83 |
| 09:50 ET | 500 | 12.8599 |
| 09:52 ET | 12667 | 12.81 |
| 09:54 ET | 200 | 12.795 |
| 09:56 ET | 684 | 12.77 |
| 09:57 ET | 100 | 12.76 |
| 09:59 ET | 800 | 12.81 |
| 10:01 ET | 5284 | 12.78 |
| 10:03 ET | 264 | 12.81 |
| 10:08 ET | 1214 | 12.84 |
| 10:10 ET | 222 | 12.82 |
| 10:12 ET | 300 | 12.79 |
| 10:15 ET | 236 | 12.8 |
| 10:17 ET | 597 | 12.79 |
| 10:19 ET | 100 | 12.77 |
| 10:21 ET | 242 | 12.75 |
| 10:24 ET | 800 | 12.76 |
| 10:26 ET | 111 | 12.76 |
| 10:30 ET | 200 | 12.785 |
| 10:32 ET | 300 | 12.7673 |
| 10:35 ET | 5638 | 12.71 |
| 10:37 ET | 100 | 12.705 |
| 10:39 ET | 9855 | 12.71 |
| 10:42 ET | 1100 | 12.76 |
| 10:44 ET | 500 | 12.76 |
| 10:46 ET | 100 | 12.77 |
| 10:48 ET | 2081 | 12.8599 |
| 10:50 ET | 300 | 12.835 |
| 10:51 ET | 300 | 12.845 |
| 10:55 ET | 100 | 12.835 |
| 10:57 ET | 434 | 12.8799 |
| 11:00 ET | 410 | 12.8232 |
| 11:02 ET | 212 | 12.85 |
| 11:08 ET | 307 | 12.835 |
| 11:09 ET | 671 | 12.835 |
| 11:11 ET | 714 | 12.84 |
| 11:18 ET | 100 | 12.84 |
| 11:22 ET | 200 | 12.78 |
| 11:24 ET | 1271 | 12.795 |
| 11:26 ET | 400 | 12.81 |
| 11:27 ET | 800 | 12.83 |
| 11:29 ET | 977 | 12.815 |
| 11:31 ET | 700 | 12.835 |
| 11:36 ET | 100 | 12.835 |
| 11:40 ET | 1113 | 12.79 |
| 11:42 ET | 404 | 12.755 |
| 11:47 ET | 559 | 12.73 |
| 11:54 ET | 102 | 12.7 |
| 11:56 ET | 627 | 12.65 |
| 11:58 ET | 200 | 12.66 |
| 12:07 ET | 9063 | 12.6 |
| 12:09 ET | 4394 | 12.55 |
| 12:12 ET | 3363 | 12.63 |
| 12:14 ET | 400 | 12.64 |
| 12:16 ET | 528 | 12.63 |
| 12:18 ET | 200 | 12.64 |
| 12:23 ET | 345 | 12.62 |
| 12:27 ET | 1510 | 12.62 |
| 12:30 ET | 428 | 12.59 |
| 12:34 ET | 784 | 12.57 |
| 12:38 ET | 550 | 12.56 |
| 12:43 ET | 100 | 12.59 |
| 12:45 ET | 300 | 12.57 |
| 12:48 ET | 200 | 12.57 |
| 12:52 ET | 1766 | 12.58 |
| 12:54 ET | 100 | 12.58 |
| 12:56 ET | 320 | 12.56 |
| 12:57 ET | 2624 | 12.6164 |
| 12:59 ET | 514 | 12.64 |
| 01:03 ET | 300 | 12.64 |
| 01:06 ET | 553 | 12.6132 |
| 01:08 ET | 1138 | 12.655 |
| 01:10 ET | 1177 | 12.6566 |
| 01:15 ET | 693 | 12.66 |
| 01:17 ET | 699 | 12.67 |
| 01:21 ET | 3581 | 12.6501 |
| 01:24 ET | 100 | 12.66 |
| 01:26 ET | 1218 | 12.66 |
| 01:30 ET | 207 | 12.66 |
| 01:32 ET | 1634 | 12.69 |
| 01:35 ET | 500 | 12.68 |
| 01:39 ET | 630 | 12.65 |
| 01:42 ET | 256 | 12.65 |
| 01:48 ET | 936 | 12.655 |
| 01:50 ET | 200 | 12.64 |
| 01:51 ET | 494 | 12.64 |
| 01:53 ET | 1473 | 12.63 |
| 01:55 ET | 424 | 12.6 |
| 01:57 ET | 200 | 12.59 |
| 02:02 ET | 736 | 12.54 |
| 02:04 ET | 552 | 12.56 |
| 02:06 ET | 500 | 12.57 |
| 02:08 ET | 2000 | 12.57 |
| 02:09 ET | 200 | 12.55 |
| 02:13 ET | 1110 | 12.52 |
| 02:18 ET | 3026 | 12.55 |
| 02:20 ET | 100 | 12.545 |
| 02:22 ET | 100 | 12.53 |
| 02:26 ET | 200 | 12.53 |
| 02:27 ET | 800 | 12.55 |
| 02:29 ET | 100 | 12.54 |
| 02:31 ET | 541 | 12.56 |
| 02:33 ET | 100 | 12.55 |
| 02:36 ET | 2313 | 12.52 |
| 02:38 ET | 1160 | 12.52 |
| 02:40 ET | 1080 | 12.53 |
| 02:42 ET | 400 | 12.52 |
| 02:44 ET | 200 | 12.52 |
| 02:45 ET | 100 | 12.52 |
| 02:47 ET | 1660 | 12.545 |
| 02:49 ET | 287 | 12.55 |
| 02:51 ET | 1000 | 12.55 |
| 02:54 ET | 300 | 12.55 |
| 02:56 ET | 1305 | 12.59 |
| 02:58 ET | 900 | 12.59 |
| 03:00 ET | 2848 | 12.61 |
| 03:02 ET | 1192 | 12.6 |
| 03:03 ET | 200 | 12.61 |
| 03:05 ET | 1829 | 12.62 |
| 03:07 ET | 928 | 12.64 |
| 03:09 ET | 1562 | 12.66 |
| 03:12 ET | 1226 | 12.63 |
| 03:14 ET | 100 | 12.63 |
| 03:16 ET | 100 | 12.62 |
| 03:18 ET | 900 | 12.59 |
| 03:20 ET | 500 | 12.575 |
| 03:21 ET | 5555 | 12.54 |
| 03:23 ET | 1616 | 12.55 |
| 03:25 ET | 2254 | 12.545 |
| 03:27 ET | 749 | 12.54 |
| 03:30 ET | 700 | 12.545 |
| 03:32 ET | 15029 | 12.515 |
| 03:34 ET | 4375 | 12.48 |
| 03:36 ET | 4265 | 12.49 |
| 03:38 ET | 3196 | 12.5 |
| 03:39 ET | 804 | 12.5 |
| 03:41 ET | 1775 | 12.49 |
| 03:43 ET | 2214 | 12.46 |
| 03:45 ET | 1099 | 12.45 |
| 03:48 ET | 3649 | 12.49 |
| 03:50 ET | 1841 | 12.5 |
| 03:52 ET | 2300 | 12.45 |
| 03:54 ET | 6750 | 12.48 |
| 03:56 ET | 6462 | 12.45 |
| 03:57 ET | 18035 | 12.4 |
| 03:59 ET | 130188 | 12.41 |
Jun 12, 2024
DJ Regenxbio Shifts CEO to Chairman, COO to Chief Executive, from 7:26AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:26AM ET on Wednesday Jun 12, 2024 by Dow JonesREGENXBIO Announces Leadership Transition, from 7:05AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 12, 2024 by Dow JonesPress Release: REGENXBIO Announces Leadership Transition, from 7:05AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 12, 2024 by Dow Jones
Jun 7, 2024
DJ REGENXBIO Initiated at Buy by Goldman Sachs, from 7:38AM ET on Friday Jun 07, 2024 by Dow Jones
7:38AM ET on Friday Jun 07, 2024 by Dow Jones
Jun 5, 2024
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 611.3M | -2.1x | --- |
Zymeworks Inc | 639.2M | -5.1x | --- |
Y-mAbs Therapeutics Inc | 522.6M | -24.0x | --- |
Urogen Pharma Ltd | 693.7M | -5.7x | --- |
SAGE Therapeutics Inc | 722.2M | -1.4x | --- |
Alector Inc | 451.1M | -3.4x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Director
- Allan Fox
- Chairman of the Board
- Kenneth Mills
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- President, Chief Executive Officer, Director
- Curran Simpson
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $611.3M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 7.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
